Anti-CD26 proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-12497462-B2
Application number	US-202117922067-A
Country	US
Kind code	B2
Filing date	Apr 29, 2021
Priority date	Apr 29, 2020
Publication date	Dec 16, 2025
Grant date	Dec 16, 2025

Abstract

Provided herein are proteins comprising an anti-CD26 antigen-binding domain. Also provided herein are methods of treating an aging-related disease or an inflammatory disease in a subject that include administering to the subject one of these proteins or a cell expressing one of these proteins.

First claim

What is claimed is:

1 . A protein comprising an anti-CD26 antigen-binding domain, wherein the anti-CD26 antigen-binding domain comprises:
(a) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 1, a CDR2 comprising SEQ ID NO: 2, and a CDR3 comprising SEQ ID NO: 3, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 4, a CDR2 comprising SEQ ID NO: 5, and a CDR3 comprising SEQ ID NO: 6; (b) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 7, a CDR2 comprising SEQ ID NO: 8, and a CDR3 comprising SEQ ID NO: 9, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 10, a CDR2 comprising SEQ ID NO: 11, and a CDR3 comprising SEQ ID NO: 12; (c) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 13, a CDR2 comprising SEQ ID NO: 14, and a CDR3 comprising SEQ ID NO: 15, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 16, a CDR2 comprising SEQ ID NO: 17, and a CDR3 comprising SEQ ID NO: 18; (d) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 19, a CDR2 comprising SEQ ID NO: 20, and a CDR3 comprising SEQ ID NO: 21, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 22, a CDR2 comprising SEQ ID NO: 23, and a CDR3 comprising SEQ ID NO: 24; (e) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 25, a CDR2 comprising SEQ ID NO: 26, and a CDR3 comprising SEQ ID NO: 27, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 28, a CDR2 comprising SEQ ID NO: 29, and a CDR3 comprising SEQ ID NO: 30; (f) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 31, a CDR2 comprising SEQ ID NO: 32, and a CDR3 comprising SEQ ID NO: 33, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 34, a CDR2 comprising SEQ ID NO: 35, and a CDR3 comprising SEQ ID NO: 36; (g) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 37, a CDR2 comprising SEQ ID NO: 38, and a CDR3 comprising SEQ ID NO: 39, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 40, a CDR2 comprising SEQ ID NO: 41, and a CDR3 comprising SEQ ID NO: 42; (h) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 43, a CDR2 comprising SEQ ID NO: 44, and a CDR3 comprising SEQ ID NO: 45, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 46, a CDR2 comprising SEQ ID NO: 47, and a CDR3 comprising SEQ ID NO: 48; (i) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 49, a CDR2 comprising SEQ ID NO: 50, and a CDR3 comprising SEQ ID NO: 51, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 52, a CDR2 comprising SEQ ID NO: 53, and a CDR3 comprising SEQ ID NO: 54; or (j) a heavy chain variable domain comprising a CDR1 comprising SEQ ID NO: 55, a CDR2 comprising SEQ ID NO: 56, and a CDR3 comprising SEQ ID NO: 57, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 58, a CDR2 comprising SEQ ID NO: 59, and a CDR3 comprising SEQ ID NO: 60.

2 . The protein of claim 1 , wherein:
the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 61 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 62; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 63 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 64; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 65 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 66; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 67 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 68; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 69 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 70; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 71 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 72; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 73 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 74; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 75 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 76; the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 77 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 78; or the heavy chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 79 and the light chain variable domain comprises a sequence that is at least 80% identical to SEQ ID NO: 80.

3 . The protein of claim 1 , wherein the protein is a multi-chain protein.

4 . The protein of claim 1 , wherein the protein is a single-chain protein.

5 . The protein of claim 1 , wherein the protein is an antibody or an antigen-binding antibody fragment.

6 . The protein of claim 1 , wherein the protein is a chimeric antigen receptor (CAR).

7 . A pharmaceutical composition comprising a protein of claim 1 and a pharmaceutically acceptable carrier.

8 . A kit comprising the pharmaceutical composition of claim 7 .

9 . A nucleic acid encoding a protein of claim 1 .

10 . A vector comprising the nucleic acid of claim 9 .

11 . A cell comprising the nucleic acid of claim 9 .

12 . The cell of claim 11 , wherein the cell is an immune cell.

13 . The cell of claim 12 , wherein the immune cell is a T cell, a B cell, or a natural killer (NK) cell.

14 . A pharmaceutical composition comprising a cell of claim 11 and a pharmaceutically acceptable carrier.

15 . A method of treating an age-related disease or an inflammatory disease in a subject, the method comprising administering to the subject a therapeutically effective amount of the protein of claim 1 .

16 . A method of treating an age-related disease or an inflammatory disease in a subject, the method comprising administering to the subject a therapeutically effective amount of the nucleic acid of claim 9 .

17 . A method of treating an age-related disease or an inflammatory disease in a subject, the method comprising administering to the subject a therapeutically effective amount of the cell of claim 11 .

18 . The method of claim 15 , wherein the subject is further administered:
(i) a therapeutically effective amount of an NK cell activating agent and/or an NK cell and/or a monoclonal antibody; and/or (ii) a therapeutically effective amount of a Treg cell activating agent and/or a Treg cell and/or a monoclonal antibody and/or an advanced glycation end product (AGE) inhibitor.

19 . The method of claim 18 , wherein the method comprises administering a therapeutically effective amount of an NK cell to the subject.

20 . A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the protein of claim 1 .

21 . A method of treating an

Assignees

• Immunitybio Inc

Inventors

• Wong Hing C
• Liu Bai
• Kong Lin
• Zhu Xiaoyun
• Spanoudis Catherine

Classifications

• C07K16/40

  against enzymes · CPC title

• A61K40/4244

  Enzymes · CPC title

• A61K40/4224

  Molecules with a "CD" designation not provided for elsewhere · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title